- Regeneron Pharmaceuticals, headquartered in Tarrytown, New York, is a leading biotechnology company focused on inventing, developing, and commercializing life-transforming medicines for serious diseases, with a strong presence in the oncology and ophthalmology markets.
- In 2026, Regeneron announced a strategic collaboration with TriNetX to access de-identified electronic health records of 300 million patients, investing up to $200 million to enhance its drug discovery and digital health solutions.
- The company also entered a partnership with Telix Pharmaceuticals to co-develop next-generation radiopharmaceutical therapies, sharing costs and profits equally, with an initial investment of $40 million for four programs.
- Regeneron's ideal buyers include healthcare providers and pharmaceutical companies seeking innovative therapies, as the company leverages its advanced genomic and proteomic databases to address unmet medical needs and drive research efficiency.
Regeneron Pharmaceuticals comprises seven distinct departments, with a total workforce of 15,110 employees. The largest department is Information Technology, employing five individuals, followed by Operations with three. Health Services contributes two employees, while Legal, Sales, and Engineering each have one. The remaining headcount is categorized under 'Other,' indicating a diverse range of functions that support the company's operations.
Regeneron Pharmaceuticals is headquartered in Tarrytown, New York, with a total of 20 employees reported in this location. The majority of the workforce is concentrated in New York, NY, while the 'Other' category accounts for 19 employees, suggesting a distributed workforce model. This geographic distribution reflects a centralized operational focus, while also accommodating remote or flexible work arrangements.
